Patents Examined by Xiaozhen Xie
  • Patent number: 11179442
    Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 11141427
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: October 12, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventor: William Mark Erwin
  • Patent number: 11141426
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 12, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventor: William Mark Erwin
  • Patent number: 11136383
    Abstract: Disclosed are compositions and methods for modulating the activity of TGF-?. More particularly, compositions and methods for modulating the release of active TGF-? from an LRRC33-TGF-? prodomain-TGF-? ternary complex are provided, as are and methods of treatment based upon such modulation.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 5, 2021
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan Springer, Chafen Lu, Yan Qin, Aiping Jiang
  • Patent number: 11123430
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffective erythropoiesis as a result of having reduced GATA-1, heat shock factor and/or NFE2 levels as compared to the levels in a reference population.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: September 21, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Pedro Martinez, Naga Venkata Sai Rajasekhar Suragani
  • Patent number: 11111312
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 7, 2021
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 11090358
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 17, 2021
    Assignees: FRED HUTCHINSON CANCER RESEARCH CENTER, BLAZE BIOSCIENCE, INC.
    Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
  • Patent number: 11078244
    Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: August 3, 2021
    Assignees: Ferring B.V., Brookhaven Science Associates, LLC
    Inventors: Paul Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
  • Patent number: 11059907
    Abstract: Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Robert Joseph Brommage, Jr., Xiao Feng, Seokjoo Hong, Gregory Landes, Jeff Liu, David George Potter, David Reed Powell
  • Patent number: 11058801
    Abstract: The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: July 13, 2021
    Assignee: BioMimetic Therapeutics, LLC
    Inventors: Charles E. Hart, Samuel E. Lynch, Conan S. Young, Dan Perrien
  • Patent number: 11040092
    Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: June 22, 2021
    Assignee: CYTONICS CORPORATION
    Inventors: Lewis Hanna, John David Laughlin, Shawn Robert Browning
  • Patent number: 11041157
    Abstract: Provided in the present invention are a Slit2D2-HAS fusion protein and the use thereof against tumours. The fusion protein can significantly inhibit the migration of tumour cells. Also provided in the present invention are a pharmaceutical composition comprising the fusion protein and a method for preparing the fusion protein.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: June 22, 2021
    Inventor: Huashun Li
  • Patent number: 11034741
    Abstract: Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 15, 2021
    Assignee: NellOne Therapeutics, Inc.
    Inventor: Cymbeline T. Culiat
  • Patent number: 11028139
    Abstract: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 8, 2021
    Assignee: NEXEL CO., LTD.
    Inventors: Choong Seong Han, Dong Hun Woo, Gun Sik Cho, Jeong Seong Kim, Geun Ho An, Hye Ryeon Jeon
  • Patent number: 11021528
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Pfizer Inc., Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 10980860
    Abstract: The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: April 20, 2021
    Assignee: Ascendis Pharma A/S
    Inventors: Dirk Vetter, Ulrich Hersel, Kennett Sprogøe, Nora Kaluza, Oliver Keil, Guillaume Maitro, Harald Rau
  • Patent number: 10947285
    Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Amolyt Pharma
    Inventors: David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
  • Patent number: 10940189
    Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 9, 2021
    Assignee: CYTONICS CORPORATION
    Inventors: Lewis Hanna, John David Laughlin, Shawn Robert Browning
  • Patent number: 10898497
    Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: January 26, 2021
    Assignee: REGENEXX, LLC
    Inventor: Christopher J. Centeno
  • Patent number: 10849967
    Abstract: A nucleic acid molecule encoding a chimeric chondroitin sulfate proteoglycan 4 (CSPG4) protein, wherein the chimeric CSPG4 protein comprises, from the N-terminal to the C-terminal: i) a first portion derived from the human CSPG4 sequence and a second portion derived from the canine CSPG4 sequence or ii) a first portion derived from the canine CSPG4 sequence and a second portion derived from the human CSPG4 sequence.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: December 1, 2020
    Assignee: Università degli Studi di Torino
    Inventors: Federica Cavallo, Paolo Buracco, Federica Riccardo, Maddalena Arigoni, Elena Quaglino, Raffaele Adolfo Calogero, Soldano Ferrone